Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
>
Webinar presenters John Fox, MD, MHA, Brian D. Piening, PhD, and Pierre Del Moral, PhD, MBA discuss how your lab can navigate TSO Comprehensive reimbursement by engaging with your payers, which tools to use and information to highlight during the billing processes.
April 8, 2025—Techcyte, Pramana, and Aiosyn, announced a collaboration to integrate AI-powered breast and kidney histopathology analysis directly into a digital pathology workflow.
April 4, 2025—Paige announced that the FDA has granted breakthrough device designation to Paige PanCancer Detect, an AI-assisted diagnostic application intended to assist pathologists in the detection of foci that are suspicious for cancer from multiple tissues and organs.
April 3, 2025—Pillar Biosciences announced it has received nationwide Medicare coverage by the Centers for Medicare and Medicaid Services for the OncoReveal CDx pan-cancer solid tumor in vitro diagnostic next-generation sequencing kit.
Webinar presenters Melanie Pollan, PhD, Alan H. B. Wu, PhD, and Christopher DeFilippi, MD, discuss how the Atellica IM TnIH assay can be used to aid in offering rapid and accurate detection of AMI, helping lead to a faster diagnosis (versus contemporary Troponin assays); it can now also assist clinicians to identify future death and cardiovascular event risk based on the new prognosis indication for use.
April 2, 2025—Werfen announced the commercialization of its ACL Top Family 70 series hemostasis testing systems in North America, following FDA 510(k) clearance and Health Canada licensure.
April 1, 2025—The U.S. District Court for the Eastern District of Texas ruled on March 31 in favor of the laboratory plaintiffs in the two consolidated cases challenging the validity of the Food and Drug Administration’s final rule on laboratory-developed tests.
Partner with us to harness scientific expertise and streamline your product development and manufacturing process. Learn More.
March 31, 2025—Siemens Healthineers announced that its Innovance Antithrombin assay has achieved FDA clearance for a new claim allowing it to be used as a companion diagnostic test for people receiving treatment with fitusiran (Qfitlia, Sanofi), a hemophilia therapy.
March 27, 2025—Techcyte announced the launch of Fusion, a standards-based, SaaS platform designed to unify anatomic and clinical pathology workflows.
